Llama-Derived Nanobody May Tread Narrow Anticancer Path | GEN
A sure-footed llama-derived antibody keeps to GPCR components that lead to therapeutically promising areas, while avoiding those that could lead to adverse side effects
Drugs based on llama-derived nanobody might head off disease-associated signaling while preserving signaling required for normal cellular function
Interesting news, scientists are targeting G & not GPCR by using a Nn5 that comes from llama. Nanobody binds tightly to G beta-gamma (Gβγ), but not to another part of the GPCR, G alpha (Gα).